RECELL®
Autologous Cell Harvesting Device

RECELL®単独使用による顔面熱傷治療後の色素再生

CASE STUDY

Jeffrey Carter, MD
University Medical Center, New Orleans, LA

患者の状態

未知の可燃性液体と火炎による11% TBSAの顔面部への深達性部分層熱傷を受傷した31歳女性（図A）.



結語

本症例では11%TBSAの顔面部深達性部分層熱傷に対し、自家細胞懸濁液（Spray-On SkinTM Cells）を単独使用した治療効果が示された。術後9日後には創部の完全上皮化が確認された。

RECELL単独使用により、周辺の皮膚との色相と近い状態にまで色素が再生した。

治療日 A



術後6日 B



術後9日 C



術後2か月 D



術後3か月 E



術後12か月 F

治療法

日 日に の に対し を し、 後、er r で を た。 治療 創部 日後、顔面部の自 治 が いとの に た。顔面部に対し、術 に が確認で まで、 ersa e によ を た。 を顔面部に使用し 日後、創傷部の と が したた 、顔面部 のRECELL使用が された。RECELL を使用し、Spray-On SkinTM Cellsを 、 の 用を た。 の後の治療部 の にはTel aTMClear er r を使用した。

CLINICAL OUTCOME

On post-op Day 6, dressings were removed (Figure B). At post-op Day 9, the patient presented with 100% re-epithelization and no signs of infection or inflammation (Figure C). The patient continued to show progressive re-pigmentation 2 months post-treatment (Figure D), 3 months post-treatment (Figure E) and 12 months post-treatment (Figure F).

RECELL®
Autologous Cell Harvesting Device

For Important Safety Information, refer to back page.

avita medical

RECELL®
Autologous Cell Harvesting Device

Visit RECELLsystem.com to learn more.

RECELL EASE OF USE—IMPORTANT SAFETY INFORMATION

INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds. The RECELL Device is used by an appropriately-licensed healthcare professional at the patient's point of care to prepare autologous Spray-On Skin™ Cells for direct application to acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients.

CONTRAINDICATIONS: RECELL is contraindicated for: the treatment of wounds clinically diagnosed as infected or with necrotic tissue, the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann's) solution, patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.

WARNINGS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL is provided sterile and is intended for single-use. Do not use if packaging is damaged or expired. Choose a donor site with no evidence of cellulitis or infection and process skin immediately. A skin sample should require between 15 and 30 minutes contact with Enzyme. Contact in excess of 60 minutes is not recommended. RECELL Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.

PRECAUTIONS: RECELL is not intended for use without meshed autograft for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL without meshed autograft have not been established for treatment of partial-thickness burn wounds: on the hands and articulating joints, >320 cm^2, in patients with wounds totaling >20% total body surface area (TBSA). The safety and effectiveness of RECELL with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, and in patients younger than 28 days of age (neonates).

SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL have not been established for treatment of acute thermal partial-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions For Use.

MA_Carter_Case_029_Video_Rev2

RECELL®
Autologous Cell Harvesting Device

avita medical